Literature DB >> 26235444

Liver injury is associated with mortality in sickle cell disease.

J J Feld1,2, G J Kato3,4, C Koh1, T Shields3, M Hildesheim3, D E Kleiner5, J G Taylor3, N G Sandler6, D Douek6, V Haynes-Williams1, J S Nichols3, J H Hoofnagle1, T Jake Liang1, M T Gladwin3,4, T Heller1.   

Abstract

BACKGROUND: Increased life expectancy in sickle cell disease (SCD) has resulted in greater recognition of the consequences of repeated intravascular vaso-occlusion and chronic haemolysis to multiple organ systems. AIM: To report the long-term consequences of liver dysfunction in SCD.
METHODS: A cohort of SCD patients was prospectively evaluated at the National Institutes of Health (NIH) Clinical Center. The association of mortality with liver enzymes, parameters of liver synthetic function and iron overload was evaluated using Cox regression.
RESULTS: Exactly, 247 SCD patients were followed up for 30 months of whom 22 (9%) died. After controlling for predictors, increased direct bilirubin (DB), ferritin, alkaline phosphatase and decreased albumin were independently associated with mortality. In a multivariable model, only high DB and ferritin remained significant. Ferritin correlated with hepatic iron content and total blood transfusions but not haemolysis markers. Forty patients underwent liver biopsies and 11 (28%) had fibrosis. Twelve of 26 patients (48%) had portal hypertension by hepatic venous pressure gradient (HVPG) measurements. All patients with advanced liver fibrosis had iron overload; however, most patients (69%) with iron overload were without significant hepatic fibrosis. Ferritin did not correlate with left ventricular dysfunction by echocardiography. DB correlated with bile acid levels suggesting liver pathology. Platelet count and soluble CD14 correlated with HVPG indicating portal hypertension.
CONCLUSIONS: Ferritin and direct bilirubin are independently associated with mortality in sickle cell disease. Ferritin likely relates to transfusional iron overload, while direct bilirubin suggests impairment of hepatic function, possibly impairing patients' ability to tolerate systemic insults. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26235444      PMCID: PMC6478018          DOI: 10.1111/apt.13347

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Nodular regenerative hyperplasia of the liver and focal global glomerulosclerosis associated with sickle cell anemia.

Authors:  Khalid A Al-Mukhaizeem; Esther Lamoureux; Arthur Rosenberg; Averell H Sherker
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

Review 2.  Sickle cell hepatopathy.

Authors:  S Banerjee; C Owen; S Chopra
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

3.  Progression of iron overload in sickle cell disease.

Authors:  N F Olivieri
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

4.  Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis.

Authors:  M Deschênes; J P Villeneuve
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

5.  Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.

Authors:  Javier Fernández; Miquel Navasa; Juliá Gómez; Jordi Colmenero; Jordi Vila; Vicente Arroyo; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

6.  Survival of children with sickle cell disease.

Authors:  Charles T Quinn; Zora R Rogers; George R Buchanan
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

7.  Chronic liver disease mortality in the United States, 1990-1998.

Authors:  Sirenda Vong; Beth P Bell
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

8.  Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites.

Authors:  José Such; Rubén Francés; Carlos Muñoz; Pedro Zapater; Juan A Casellas; Ana Cifuentes; Francisco Rodríguez-Valera; Sonia Pascual; Javier Sola-Vera; Fernando Carnicer; Francisco Uceda; José M Palazón; Miguel Pérez-Mateo
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

9.  Causes of death in sickle cell disease: an autopsy study.

Authors:  Elizabeth A Manci; Donald E Culberson; Yih-Ming Yang; Todd M Gardner; Randall Powell; Johnson Haynes; Arvind K Shah; Vipul N Mankad
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

10.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  19 in total

Review 1.  Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Authors:  Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh
Journal:  Semin Hematol       Date:  2018-04-25       Impact factor: 3.851

Review 2.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

3.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

4.  Severe cardiac iron toxicity in two adults with sickle cell disease.

Authors:  Hellen Oduor; Caterina P Minniti; Alessandra Brofferio; Ahmed M Gharib; Khaled Z Abd-Elmoniem; Matthew M Hsieh; John F Tisdale; Courtney D Fitzhugh
Journal:  Transfusion       Date:  2016-12-26       Impact factor: 3.157

Review 5.  Management of liver complications in sickle cell disease.

Authors:  Abid R Suddle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 6.  Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.

Authors:  Tirthadipa Pradhan-Sundd; Gregory J Kato; Enrico M Novelli
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

Review 7.  Clinical management of sickle cell liver disease in children and young adults.

Authors:  Eirini Kyrana; David Rees; Florence Lacaille; Emer Fitzpatrick; Mark Davenport; Nigel Heaton; Sue Height; Marianne Samyn; Fulvio Mavilio; Valentine Brousse; Abid Suddle; Subarna Chakravorty; Anita Verma; Girish Gupte; Marki Velangi; Baba Inusa; Emma Drasar; Nedim Hadzic; Tassos Grammatikopoulos; Jonathan Hind; Maesha Deheragoda; Maria Sellars; Anil Dhawan
Journal:  Arch Dis Child       Date:  2020-11-11       Impact factor: 3.791

8.  Nodular regenerative hyperplasia in X-linked agammaglobulinemia: An underestimated and severe complication.

Authors:  Cristiane J Nunes-Santos; Christopher Koh; Anjali Rai; Keith Sacco; Beatriz E Marciano; David E Kleiner; Jamie Marko; Jenna R E Bergerson; Michael Stack; Maria M Rivera; Gregory Constantine; Warren Strober; Gulbu Uzel; Ivan J Fuss; Luigi D Notarangelo; Steven M Holland; Sergio D Rosenzweig; Theo Heller
Journal:  J Allergy Clin Immunol       Date:  2021-06-01       Impact factor: 10.793

9.  Serum or plasma ferritin concentration as an index of iron deficiency and overload.

Authors:  Maria Nieves Garcia-Casal; Sant-Rayn Pasricha; Ricardo X Martinez; Lucero Lopez-Perez; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

Review 10.  Sickle Hepatopathy.

Authors:  Dibya L Praharaj; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2020-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.